Advancements in machine learning are transforming immunotherapy management by improving the prediction of patient responses in metastatic non-small cell lung cancer (NSCLC). Novel algorithms analyze complex clinical and molecular data to stratify patients based on likely benefit, enabling more personalized treatment plans. This tailored approach aims to optimize therapeutic efficacy, mitigate adverse effects, and inform clinical decision-making in oncology, representing a significant leap forward in precision medicine for lung cancer.